Articles
5 June 2009
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
https://doi.org/10.4081/hmr.v1i11.352

The Intergroupe Francophone du Myélome experience with thalidomide

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
191
Views
284
Downloads

Authors

Jean-Luc Harousseau
support@pagepress.org
Michel Attal
Thierry Facon
Ibrahim Yakoub-Agha
The Intergroupe Francophone du Myélome (IFM) has conducted studies of thalidomide as treatment for relapsed or refractory multiple myeloma (MM) and as first-line therapy. One study comparing two doses of thalidomide (100 vs 400 mg/d) in relapsed patients has not yet been analyzed. Another study testing low-dose thalidomide in combination with melphalan and prednisone (MP) in elderly patients (>75 years) with newly diagnosed MM is ongoing. Three studies are presented here. Of these, one phase 2 study in relapsed/refractory patients has already been published; the other two have been presented in meetings only.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



The Intergroupe Francophone du Myélome experience with thalidomide. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.352